Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas 77843, USA.
Institute of Biosciences and Technology, Texas A&M University, Houston, Texas 77030, USA.
Toxicol Sci. 2022 Jul 28;188(2):143-152. doi: 10.1093/toxsci/kfac061.
Much has been written and said about the promise and excitement of microphysiological systems, miniature devices that aim to recreate aspects of human physiology on a chip. The rapid explosion of the offerings and persistent publicity placed high expectations on both product manufacturers and regulatory agencies to adopt the data. Inevitably, discussions of where this technology fits in chemical testing paradigms are ongoing. Some end-users became early adopters, whereas others have taken a more cautious approach because of the high cost and uncertainties of their utility. Here, we detail the experience of a public-private collaboration established for testing of diverse microphysiological systems. Collectively, we present a number of considerations on practical aspects of using microphysiological systems in the context of their applications in decision-making. Specifically, future end-users need to be prepared for extensive on-site optimization and have access to a wide range of imaging and other equipment. We reason that cells, related reagents, and the technical skills of the research staff, not the devices themselves, are the most critical determinants of success. Extrapolation from concentration-response effects in microphysiological systems to human blood or oral exposures, difficulties with replicating the whole organ, and long-term functionality remain as critical challenges. Overall, we conclude that it is unlikely that a rodent- or human-equivalent model is achievable through a finite number of microphysiological systems in the near future; therefore, building consensus and promoting the gradual incorporation of these models into tiered approaches for safety assessment and decision-making is the sensible path to wide adoption.
人们已经撰写和讨论了很多关于微生理系统的前景和兴奋点,这是一种旨在在芯片上重现人体生理功能的微型设备。微生理系统的产品供应迅速增加,宣传持续不断,这使得产品制造商和监管机构都对采用这些数据寄予厚望。不可避免的是,关于这项技术如何适应化学测试模式的讨论仍在继续。一些终端用户成为了早期采用者,而另一些用户则采取了更为谨慎的方法,因为其成本高且使用效果不确定。在这里,我们详细介绍了一个公私合作的经验,该合作是为了测试各种微生理系统而建立的。我们共同提出了一些关于在微生理系统的应用背景下,在决策过程中使用微生理系统的实际方面的考虑因素。具体来说,未来的终端用户需要为广泛的现场优化做好准备,并能够获得广泛的成像和其他设备。我们认为,细胞、相关试剂以及研究人员的技术技能,而不是设备本身,是成功的最关键决定因素。从微生理系统的浓度-反应效应推断到人体血液或口服暴露,复制整个器官的困难以及长期功能仍然是关键挑战。总的来说,我们得出的结论是,在不久的将来,通过有限数量的微生理系统实现啮齿动物或人类等效模型的可能性不大;因此,建立共识并促进这些模型逐渐纳入分层方法,用于安全性评估和决策,是广泛采用的明智途径。